Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.  All of the Company's drug candidates are new molecular entities discovered internally by its dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. Lexicon Pharmaceuticals has advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome.

Company Growth (employees)
Spring, US
Size (employees)
168 (est)
Lexicon Pharmaceuticals was founded in 1995 and is headquartered in Spring, US

Key People/Management at Lexicon Pharmaceuticals

Raymond Debbane

Raymond Debbane

Chairman of the Board
Pablo Lapuerta

Pablo Lapuerta

Executive Vice President of Clinical Development and Chief Medical Officer
Jeffrey L. Wade

Jeffrey L. Wade

Executive Vice President and Chief Financial Officer
James F. Tessmer

James F. Tessmer

Vice President of Finance and Accounting
Alan J. Main

Alan J. Main

Executive Vice President, Commercial Supply Operations
Lonnel Coats

Lonnel Coats

President and Chief Executive Officer and Director

Lexicon Pharmaceuticals Office Locations

Lexicon Pharmaceuticals has offices in Spring, The Woodlands, Boston, Philadelphia and in 27 other locations
Spring, US (HQ)
8800 Technology Forest Place
Show all (31)

Lexicon Pharmaceuticals Financials and Metrics

Lexicon Pharmaceuticals Financials

Lexicon Pharmaceuticals's revenue was reported to be $83.3 m in FY, 2016

Revenue (Q3, 2017)

26.9 m

Gross profit (Q3, 2017)

26.3 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

(30.7 m)

EBIT (Q3, 2017)

(29.5 m)

Market capitalization (22-Dec-2017)

1.1 b

Cash (30-Sep-2017)

83.3 m
Lexicon Pharmaceuticals's current market capitalization is $1.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


2.2 m22.9 m130 m83.3 m

Revenue growth, %



(102.4 m)(100.4 m)1.5 m(137.2 m)

EBIT margin, %

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


238 k277 k676 k419 k1.8 m376 k566 k20.1 m27.7 m18.3 m12.1 m26.9 m

Cost of goods sold

225 k537 k599 k

Gross profit

18.1 m11.5 m26.3 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015


37.5 m137.3 m46.6 m

Current Assets

134.6 m369 m357.9 m


44.5 m44.5 m44.5 m

Total Assets

274.2 m471.4 m475.6 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


9.7 m61.7 m24.7 m38.4 m38.8 m2.5 m30.7 m83.3 m

Accounts Receivable

(3.1 m)


236 k811 k4.5 m

Current Assets

313.8 m288.9 m492.2 m439.5 m398.7 m279.1 m247.2 m214 m
    USDFY, 2013FY, 2014FY, 2015

    Depreciation and Amortization

    2.1 m

    Accounts Receivable

    (4.1 m)

    Cash From Operating Activities

    (91.1 m)(75.6 m)(175.6 m)

    Purchases of PP&E

    (1.7 m)(80 k)(231 k)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (34.9 m)(73 m)(109 m)(34.9 m)(70 m)(30.7 m)

    Depreciation and Amortization

    2.2 m644 k1.2 m1.7 m355 k601 k661 k521 k1 m1.5 m634 k1.6 m

    Accounts Receivable

    483 k319 k509 k625 k865 k719 k963 k170 k(107 k)173 k(1.2 m)2.5 m(3.1 m)


    4.5 m
      USDY, 2017


      160.4 k

      Financial Leverage

      4.2 x
      Show all financial metrics

      Lexicon Pharmaceuticals Operating Metrics

      FY, 2016

      Phase I Trials




      Phase Preclinical


      Phase III Trials

      Show all operating metrics

      Lexicon Pharmaceuticals Market Value History

      Lexicon Pharmaceuticals's Web-traffic and Trends

      Lexicon Pharmaceuticals Online and Social Media Presence

      Lexicon Pharmaceuticals Company Life and Culture

      You may also be interested in